| Followers | 194 |
| Posts | 20503 |
| Boards Moderated | 0 |
| Alias Born | 09/18/2017 |
Saturday, May 25, 2019 12:05:09 AM
Recent OTLK News
- Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering • GlobeNewswire Inc. • 03/24/2026 11:00:00 AM
- Outlook Therapeutics Announces Proposed Public Offering • GlobeNewswire Inc. • 03/23/2026 09:30:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/23/2026 09:18:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/16/2026 01:00:28 PM
- Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note • GlobeNewswire Inc. • 03/16/2026 12:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/10/2026 08:30:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 10:01:18 PM
- Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg) • GlobeNewswire Inc. • 03/05/2026 09:15:00 PM
- Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland • GlobeNewswire Inc. • 02/19/2026 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/18/2026 10:01:25 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 10:01:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 01:30:36 PM
- Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 02/17/2026 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 10:00:40 PM
- Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter • GlobeNewswire Inc. • 02/11/2026 01:45:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 01/26/2026 10:03:09 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/26/2026 10:02:06 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 01/26/2026 10:01:25 PM
- Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development • GlobeNewswire Inc. • 01/06/2026 01:35:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 12:30:35 PM
- Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD • GlobeNewswire Inc. • 12/31/2025 09:15:00 PM
- Outlook Therapeutics Announces New Employment Inducement Grants • GlobeNewswire Inc. • 12/26/2025 10:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 12/19/2025 10:01:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2025 01:30:50 PM
- Outlook Therapeutics Reports Financial Results for Fiscal Year 2025 • GlobeNewswire Inc. • 12/19/2025 01:05:00 PM
FEATURED ECGI Signs Definitive $25 Million Agreement to Acquire RezyFi • Mar 24, 2026 8:30 AM
Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction Client • BLOZF • Mar 19, 2026 12:45 PM
ECGI Building in Crypto's Top-Performing Sector as Tokenized Real-World Assets Surge Past $26 Billion • ECGI • Mar 19, 2026 8:30 AM
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
